Journal of Advanced Scientific Research

Available online through https://sciensage.info

ISSN
0976-9595
Review Article

The Future of Drug Development: Leveraging AI for Faster and Safer Innovation

Prarit Tomar, Falguni Goel, Akansha Pal, Vipin Kumar Garg*
Department of Pharmaceutical Technology, Meerut Institute of Engineering & Technology (MIET), Meerut, India.
*Corresponding author: vipin.garg@miet.ac.in
Received: 17-03-2025; Accepted: 10-04-2025; Published: 29-04-2025

https://doi.org/10.55218/JASR.2025160402

ABSTRACT

Integration of AI in drug development is poised to revolutionize the pharmaceutical industry by streamlining the drug discovery process, reducing costs, and improving safety. The conventional drug development process is notoriously slow and expensive, with high failure rates in late-stage clinical trials. Nonetheless, the use of AI is able to facilitate the process more rapidly based on enormous amounts of biological, chemical, and clinical information so as to identify novel drug targets, forecast drug candidate efficacy and toxicity, and select the most favorable clinical trials. Machine algorithms can interpret complex sets of information and identify hidden patterns within these and, thereby pave the way to improved therapy. AI technologies also facilitate the development of tailored treatments according to individual genetic profiles that can allow precision medicine. It also foretells drug side effects, and its sophisticated pharmacokinetics promote drug safety, which is lower during the clinical phase of this new drug, though some challenges are to be met before AI can be applied widely for drug discovery. These are threats to data privacy, good-quality datasets, and regulatory frameworks. But the future of drug discovery is rosy with AI powering quicker, more affordable, and safer innovation, revolutionizing the medical research environment and improving patient results.

Keywords: Artificial intelligence, Drug development, Drug compliance, Patient adherence, Future prospects, Challenges and constraints.

INTRODUCTION

Pharmaceutical development has also undergone a miraculous transformation over the years, from the traditional ways of discovery to the employment of newer technologies such as artificial intelligence. Drug discovery in the initial years relied heavily on serendipity and hit-or-miss methods, where natural products were screened to identify their therapeutic activity. As scientific understanding grew, scientists increasingly recognized specific biochemical targets within the body and with more rational strategies for designing drugs.[1] Yet nevertheless, despite all these advances, conventional drug discovery has continued to be marred by disadvantages like high cost, long development times, and a high rate of failures.

One of the biggest challenges of the traditional drug development pipeline is its cost and time to put a new drug onto the market. The process typically takes over 10 years and entails tens of thousands of preclinical and clinical testings. In the majority of instances, the drug candidates are cut off during these stages due to toxicity, inability to be effective, or adverse side effects that were not anticipated.[2] Second, the complexity of human diseases in most instances has proven to be difficult to develop drugs that would address some of the molecular targets well without unexpected side effects. Conventional drug development processes are limit-constrained and hence, have pushed development along a direction that would ensure efficiency and increments in success rate.

Over the last decade, artificial intelligence has transformed contemporary medicine and revolutionized the drug development paradigm. AI-based algorithms are capable of browsing vast amounts of chemical and biological data and identifying potential drug leads at a faster and more reliable rate than classical methods.[2] Machine learning algorithms have the ability to forecast the drug-target interaction, estimate its toxicity, and design its chemical structure for maximum efficacy. This has the result of significantly decreasing early-stage drug discovery time and enhancing the odds of striking likely candidates.

Furthermore, AI innovations are revolutionizing the field of clinical trials with patient stratification, prediction of response to therapy, and cutting-edge trial design. Through deep analytics and real-world data, AI allows scientists to identify the most suitable candidates for clinical trials at lower costs and better chances of success.[3] Furthermore, AI is also at the core of personalized medicine, which allows one to create personalized treatment in line with one's genetics, lifestyle, and medical history.

As AI becomes more powerful, so must its impact on drug development. By taking advantage of the weaknesses of traditional techniques, AI is accelerating the discovery of new medicines, improving the care of patients, and opening the door to a more streamlined, targeted system of medicine. Difficulties around data quality, regulatory matters, and ethics can still arise, but the

intersection of AI in drug discovery is now promising its way into transforming medicine and assisting with resolving many of the most impactful medical challenges of our time.[4]

Artificial Intelligence in Drug Discovery

Artificial intelligence is transforming drug discovery by making it more efficient, cost-effective, and successful at bringing new medicines to market.[5] Conventional drug discovery techniques are slow and labor-intensive, but AI-powered strategies use enormous datasets and computational capabilities to speed up the process. With the combination of sophisticated algorithms, scientists can discover potential drug leads, anticipate how they will interact with biological targets, and design their chemical structure more accurately than ever before [6] (Fig. 1).

Machine learning and deep learning are pivotal in contemporary drug discovery through predictive modeling and data-informed decision-making. The two AI methods examine intricate biological and chemical data sets to identify patterns that are hard to spot for humans. Machine learning methods are especially efficient in estimating drug-protein interactions, toxicity risk evaluation, and molecular property optimization for better efficacy.[7] Deep learning algorithms, which mimic the structure and processes of the human brain, can scan vast amounts of genomic, proteomic, and chemical data to identify new drug leads and streamline the discovery pipeline. With these advanced computer programs, AI reduces the cost and time of drug design while improving the accuracy of prediction.[8]



Fig. 1: Artificial intelligence (AI) in discovering and developing new drugs: facilitating innovative advancement along the drug development pipeline: A depiction above portrays the emphasis on the role of AI technologies at various intervals of target selection, molecular modeling and clinical trial planning and evaluation among many others revolutionizing the shelf life of drug products manufacturing processes

Target identification and validation are crucial in drug discovery as the future of a new treatment depends on making the optimal selection of the most promising biological target. AI goes one step ahead and scans enormous genomic and proteomic information to find targets of disease relevance. With experimental and clinical data and machine learning models, scientists can rank targets by their potential to be valuable points of drug intervention. AI also facilitates validation through predicting probable side effects and establishing the viability of targeting particular proteins. The process reduces the risk of late-stage failures, and drug development is streamlined and focused.

High-throughput screening, the basis of drug discovery, involves screening for candidate drug leads from large chemical libraries. AI-based strategies have transformed the process by speeding up the management of data and maximizing the detection of hits. Traditional screening techniques are time- and labor-intensive, while AI algorithms can quickly predict compound biological activity, eliminate non-viable options, and suggest high-potential compounds. Deep learning virtual screening enhances this feature even more by virtually replicating the drug-target interaction *in-silico* to reduce dependence on bulk laboratory tests. In addition to accelerating the process of screening, this computer-based approach also optimizes the likelihood of discovering a successful drug candidate.

Day by day, AI is becoming stronger and will continue to be a dominant force in drug discovery.[9] With machine learning, deep learning, and AI-based screening methods, researchers can liberate themselves from the limitations of traditional drug discovery and provide more efficient and safer drugs to patients faster than ever before. The convergence of AI in this field promises the dawn of a new era of precision medicine in which data-driven solutions enable innovations in novel healthcare and therapeutic discovery.[10]

AI in Preclinical and Clinical Research

Artificial intelligence is transforming both preclinical and clinical research into greater efficiency, reduced failure rates, and faster new drug development. Traditional forms of research are laborious experiments, costly clinical trials, and huge failure rates in the form of unexpected toxicity or insufficient efficacy.[11] AI-powered tools are transforming such a process in the form of large-scale data analysis, drug behavior prediction, and optimal-in-class trial design for providing new drug success.[12]

Drug-target interaction prediction is the most important application of AI in drug discovery. The understanding of the interaction of a drug with a biological target is the key to its efficacy and toxicity prediction (Table 1). AI models and deep learning models sift through enormous sets of molecular structures and biological targets to determine the potential drug candidates. The models can accurately predict binding affinities, the mode of interaction, and potential off-target effects. Researchers can screen and rank compounds quickly with the assistance of AI much faster and at much lower expense than during early drug discovery.[13]

AI also plays a crucial part in preclinical toxicology and safety assessment, which are turning points of drug development to

determine that potential medicines don't trigger unwanted effects. Traditional toxicology tests rely on high-volume animal testing, which is expensive, time-consuming, and sometimes indeterminate in determining human response. Artificial intelligence-based predictive models, having been pre-trained on vast toxicological databases, are capable of assessing future safety risks by chemical structure analysis, metabolic pathway analysis, and biological interaction analysis.[14] AI-based models provide early warnings for a drug's toxicity profile, reducing animal testing requirements and increasing the chances of identifying safe compounds for human trials. By incorporating AI into preclinical testing, researchers can detect potential safety issues earlier in the development pipeline, thereby preventing costly late-stage failures.[15]

Another field where AI is having a big splash is in the design of clinical trials. Clinical trials are normally the most time-consuming and costly stage of drug development, and ineffective trial design, selection of patients, or side effects derail numerous potential treatments. AI optimizes trials by reading across patient data, identifying suitable subjects, and making estimates of treatment effects. Machine learning programs can stratify patient groups by clinical, demographic, and genetic features so that trials can be conducted among the most likely candidates to take advantage of the drug.[16] Adaptive trial designs using AI can adjust the dosage, treatment duration, or even patient enrollment in real time based on outcomes. This adaptive approach ensures maximum trial success and accelerates approval.

The use of AI in preclinical and clinical trials is revolutionizing drug development. With predictive modeling, data-driven safety assessment, and AI-optimized trial design, scientists are making processes leaner, saving money, and getting treatments to patients more quickly.[17] As AI continues to improve, its impact on pharmaceutical research will be even more significant, and it will keep driving the future of precision medicine and improved patient outcomes across the world.[18]

Accelerating Drug Repurposing with AI

Artificial intelligence is being used in the novel process of drug repurposing, a process that utilizes already approved drugs in an effort to find new therapeutic uses for them. The conventional drug discovery process is lengthy and costly and it takes more than a decade to have a new drug on the market.[19] Repositioning existing approved drugs provides a quicker and cheaper option *via* the leverage of pre-existing safety and efficacy data. AI adds speed by quickly scanning huge amounts of data to identify latent patterns between drugs and diseases and precisely predict new applications.[20]

One of the greatest advantages of AI in drug repurposing is that it can recognize new indications for drugs that have already been approved by looking at complex interactions between chemicals and biology. Drugs will most likely have more than one molecular target, and AI models can methodically examine these as a method to identify new therapeutic activity.[21] With machine learning algorithms that have been trained on genomic, proteomic, and clinical information, scientists can predict whether a drug originally discovered for one disease can theoretically be repurposed to treat another. This approach has been best shown to be effective in discovering treatments for orphan diseases, in which traditional drug discovery is not economically viable.[22]

AI-based data mining is essential to speed up drug repurposing by collecting huge amounts of knowledge from various sources such as biomedical literature, clinical trials, and real-world patient information. NLP algorithms read millions of research articles and clinical reports to select promising drug-disease pairs that could have gone unnoticed.[23] In addition, network analysis using AI graphs intricate biological pathways to show how current drugs can act on various disease mechanisms. By combining these data-driven methods, AI greatly speeds up and enhances the accuracy of drug repurposing (Fig. 2).[24]

Some successful cases highlight the potential of AI-driven drug repurposing in addressing key medical challenges. In the COVID-19 pandemic, AI has been applied to discover available drugs that have antiviral effects and screen them quickly as candidate drugs like remdesivir and baricitinib. In cancer chemotherapy, AI has also repurposed thalidomide to treat multiple myeloma, even though it was initially used as a sedative.[25] Equally, scientists have employed AI to find that some antidepressants have neuroprotective properties, offering a spark of hope for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's. These are just some of the examples of how AI-facilitated repurposing can yield cure treatments within a tenth of the time it takes to develop drugs conventionally.[26]

By incorporating AI into drug repurposing pipelines, the pharma industry can appropriately increase the therapeutic value of existing drugs, lower the cost of development, and speed up the availability of new medicines to patients. With advancing AI technology, so too will its potential to repurpose medicines to address unmet clinical needs, changing the paradigm by which we treat disease and discover drugs.[27]

Enhancing Drug Safety and Risk Assessment

Artificial intelligence is transforming drug safety and risk management by complementing pharmacovigilance, forecasting unsafe effects, and facilitating personalized medicine. Current methods of monitoring drug safety include clinical trials and post-

Fig. 2: Accelerating drug repurposing with AI: Representing how smart reminders, personalized interventions, and real-time monitoring skills embedded into AI-enabled apps increase the levels of medication adherence and help patients remain compliant with their treatment processes.

marketing surveillance, which are burdensome and time-consuming in the detection of infrequent or delayed adverse effects.[28] AI complements this by processing enormous amounts of real-world data, detecting possible risks in advance, and enhancing patient care by evidence-based decision support.

AI contributes immensely to pharmacovigilance by being able to identify and predict adverse drug reactions better and faster than the traditional reporting mechanism. With machine learning models and natural language processing, AI is capable of scouring through electronic health records, clinical trial reports, patient feedback, and scientific literature to extract patterns that suggest the possibility of safety issues.[29] The models capture latent side effect-drug relationships that would otherwise go undetected. Automated signal detection enables regulators and healthcare professionals to act upon safety issues sooner, enhancing patient protection and limiting the potential for mass adverse reactions.[30]

Personalized medicine is also an area where AI improves drug safety by making risk stratification easier through the use of patients' individual profiles. Conventional drug development is one-size-fits-all, but AI models can analyze genetic, demographic, and clinical information to forecast how various individuals will react to certain drugs.[31] By combining genomic and biomarker information, AI assists in the identification of patients who are at greater risk of suffering adverse effects, thereby making treatment more tailored. Tailoring reduces risks of toxic side effects and allows for patients to be administered medications most appropriate to their biological makeup.[32]

Post-marketing surveillance is critical to maintaining long-term drug safety, and AI-based real-world evidence analysis has revolutionized the process. AI offers the capability to monitor large-scale data sources continuously, such as patient registries, social media, claims databases, and wearable health device data, to monitor drug performance and monitor emerging safety issues.[33] In contrast to conventional pharmacovigilance processes, which are based on spontaneous reporting, AI actively identifies risks in real-time. Machine learning algorithms assist regulatory bodies, including the FDA and EMA, in streamlining safety rules, issuing warnings, and, if needed, taking drugs off the market before they can cause havoc on a large scale.[34]

With the use of AI in drug safety and risk management, the healthcare sector can enhance pharmacovigilance, develop personalized medicine, and improve post-market surveillance. Through these technologies, patients are assured to be treated with safer drugs, minimizing the incidence of adverse effects, and enabling more preventive regulatory actions.[35] With further development of AI, its contributions to drug safety will become ever more vital, defining the future where drugs not only become more effective but even far safer across a broad array of patient populations.[36]

Challenges and Ethical Considerations

The use of artificial intelligence in drug discovery is replete with monumental opportunity, but are replete with monumental challenges and ethical issues. As the AI technologies advance, the solutions regarding data privacy, bias, explainability, and regulatory readiness have to be solved to enable making the right and ethical use of such technologies to medicine.Data security and privacy are among the major issues of AI-driven drug discovery. Huge biomedical, genomic, and patient data are needed by AI algorithms to predict well and streamline drug development processes.[37] Processing medical data is an issue in confidentiality and unauthorized access. Imposing strong data encryption, secure storage, and adherence to privacy policies like GDPR and HIPAA requires strict practices to ensure patient trust. Moreover, anonymized or synthetic data can be used in a way that mitigates the risk to privacy but makes it possible for AI to derive important insights.[38]

Bias and transparency of AI models constitute a second moral concern. AI models are no better than data used to train them, and future models may be biased or yield inaccurate results if datasets lack breadth or be inherently biased. As an instance, if the training data do not have varied distributions along patient groups, AI-based drug discovery has the risk of overlooking drugs for under-represented patient populations.[39] Ensuring fairness in AI models is through high-quality, varied data sets and robust validation to constrain bias. Transparency of AI decision-making is also critical to clinical use and regulatory approval. Explainable AI (XAI) techniques can help researchers and regulators comprehend how models make their decisions and gain confidence in AI-driven recommendations.[40]

Regulatory frameworks for drug development with AI are constantly changing, and balancing innovation and compliance is one of the biggest challenges. The current drug approval procedures were not designed with AI-based processes in mind, and new policies must be developed that account for machine learning-based drug discovery's unique features.[41] Regulatory agencies such as the FDA and EMA are trying to put stringent regulations on AI utilization in drug development, including data maintenance, model validation, and tracking real-world applications. Regulation, industry leaders, and scientists need to come together to ensure that AI-driven developments meet safety, efficacy, and ethical standards.[40]

As drug development becomes increasingly characterized by artificial intelligence, it will be paramount to overcome these challenges in an attempt to ensure that AI is utilized responsibly and justly. By putting data security first, mitigating biases, improving transparency, and evolving regulatory environments, the pharmaceutical industry can best capitalize on the advantages of AI while upholding ethical standards.[42] A future-looking and reflective approach will allow AI to lead medical innovation in a way that is beneficial to all patient groups while being able to trust AI-based healthcare solutions.[43]

Future Directions and Innovations

Future drug discovery and development will be revolutionized by radical innovations that bridge artificial intelligence and emerging technologies. AI is transforming pharmaceutical research but will have even greater influence as quantum computing, robotics, biologics, and precision medicine advance. All these will advance drug design, simplify manufacturing, and tailor therapy highly individualized for each patient.[44]

One of the most thrilling of these is the convergence of quantum computing and AI with robotics to tackle challenging biological problems at a scale heretofore unimaginable. Quantum computers can calculate humongous numbers of numbers in seconds, speeding up molecular simulations and predictions of protein folds that would

Table 1: AI in preclinical and clinical research

AI application	*Preclinical research*	*Clinical research*	*References*
Drug discovery	Identifies potential drug candidates using AI-driven molecular simulations.	Predicts drug efficacy and safety profiles from clinical trial data.	[50]
Biomarker discovery	Detects novel biomarkers using machine learning on genomic and proteomic data.	Uses AI to validate biomarkers for disease diagnosis and prognosis.	[51]
Toxicology & safety	Simulates toxicity assessments with AI models before in-vitro testing.	Assists in real-time adverse event monitoring and prediction.	[15]
Imaging & diagnostics	AI models analyze histopathological images for early disease detection.	Enhances radiology and pathology diagnostics for patient monitoring.	[52]
Clinical trial design	Predicts drug-target interactions and refines animal model selection.	AI optimizes patient recruitment and trial protocols based on real-world data.	[53]
Data management	AI processes high-throughput screening data for target identification.	Uses AI-driven natural language processing (NLP) to analyze electronic health records (EHRs).	[54]
Personalized medicine	AI tailors preclinical models for specific genetic profiles.	Recommends treatment regimens based on patient-specific data.	[55]
Regulatory compliance	Automates preclinical data documentation for regulatory approval.	AI ensures clinical trial adherence to regulatory standards.	[41]

take years on regular computers. Robotics with AI capability further augment this by automating laboratory processes, high-throughput screening, and chemical synthesis optimization.[45] Integration of these technologies will significantly shorten the drug discovery time, allowing rapid identification of new therapeutic molecules with enhanced accuracy and efficiency.

Another revolutionary space is the use of AI in biologics and personalized medicine. While classical small-molecule drugs have relatively non-specific treatments for disease, biologics such as monoclonal antibodies, gene therapy, and mRNA therapies have extremely targeted treatments for diseases. AI models are used for designing and optimizing biologics via protein structure prediction, immunogenicity prediction, and drug stabilization.[46] In addition, therapeutics can be custom-designed to order using AI and the examination of genetic and biomarker information in order to tailor the therapy to a patient's own unique biology. This has tremendous potential in cancer immunotherapy, orphan disease, and regenerative medicine, all of which are very highly personalized treatments.[47] AI is also vital in precision medicine and personalized drug development, where drugs are created according to an individual's genetic, environmental, and lifestyle variables. With AI-driven data from genomic sequencing, electronic health records, and real-world patient experience, researchers can determine the best therapies for certain populations of patients.[48] Machine learning algorithms support the prediction of drug response, identification of ideal dosing regimens, and reduction of side effects, which results in more effective and less harmful therapies. This transition towards personalized medicine represents a departure from the conventional one-size-fits-all approach to ensure that patients receive therapies personalized to their specific needs.[49]

As technology advances, its combination with quantum computing, robotics, biologics, and precision medicine will redefine the future of healthcare and drug discovery. These advances will not only accelerate the discovery of new treatments but also improve patient outcomes by offering very personalized therapies. With more investments, collaboration, and adjustments in regulations, AI-led innovation will unlock the potential for a new era of medicine that is more efficient, accessible, and personalized than ever.[7]

CONCLUSION

Artificial intelligence has revolutionized drug development by speeding up discovery, enhancing efficiency, and increasing precision in pharmaceutical research. Exorbitant expenses, protracted timelines, and excessive failure rates have long plagued conventional drug discovery and clinical trials. AI technologies have addressed these issues by harnessing big data, predictive modeling, and automation to enhance processes and decision-making. From the discovery of lead drug candidates to the design of clinical trials, AI has transformed each step of the drug development pipeline. Its use in target identification, high-throughput screening, toxicity prediction, and personalized medicine has decreased the time and cost of bringing new drugs to market by considerable amounts. With the advancement of AI in the future, its prospects in pharmaceutical research appear even brighter. The combination of AI with emerging technologies like quantum computing, robotics, and biologics will further augment drug design and manufacturing capabilities. AI-based precision medicine will spearhead the development of highly individualized treatments so therapies are tailored to a patient's specific needs on the basis of their genetic, clinical, and lifestyle profiles. Furthermore, AI in post-market monitoring and real-world evidence analysis will enhance drug safety through active risk evaluation and prompt identification of adverse effects. In spite of data privacy challenges, bias, and regulatory resilience, the further evolution of AI in drug discovery has enormous potential to revolutionize healthcare. With the adoption of AI-based innovations, the pharma industry can design safer, more efficient, and more affordable drugs, and thereby enhance patient outcomes globally. Medicine is rapidly becoming data-centric, and AI will continue to lead the development of the next era of drug discovery and development.

ACKNOWLEDGMENT

I would like to extend my sincere appreciation to CNDR MIET for the excellent facilities throughout the production of this essay.

REFERENCES

1. Miracle, A.A. and C.C. Adaobi, *The Impact of Generative AI on Healthcare*, in *Generative Artificial Intelligence (AI) Approaches for Industrial Applications*. 2025, Springer. p. 169-188.
2. Rehman, A.U., et al., *Role of artificial intelligence in revolutionizing drug discovery.* Fundamental Research, 2024.
3. Amorim, A.M., et al., *Advancing drug safety in drug development: bridging computational predictions for enhanced toxicity prediction.* Chemical Research in Toxicology, 2024. **37**(6): p. 827-849.
4. Babu, C.S., Y. Bhargavi, and P.R. Krishna, *AI-Driven Personalized Healthcare Solutions: Transforming Healthcare Delivery Through Precision, Efficiency, and Innovation.* AI-Driven Personalized Healthcare Solutions, 2025: p. 241-276.
5. Niazi, S.K. and Z. Mariam, *Artificial intelligence in drug development: reshaping the therapeutic landscape.* Therapeutic Advances in Drug Safety, 2025. **16**: p. 20420986251321704.
6. KADIRI, S.K., *CHAPTER SIX AI-IN SCREENING OF BIOACTIVE MOLECULES.* AI-Personalized Medicine Therapy, 2025: p. 180.
7. Kandhare, P., et al., *A Review on Revolutionizing Healthcare Technologies with AI and ML Applications in Pharmaceutical Sciences.* Drugs and Drug Candidates, 2025. **4**(1): p. 9.
8. Gandhewar, N., et al., *Leveraging Deep Learning for Genomics Analysis: Advances and Applications.* Genomics at the Nexus of AI, Computer Vision, and Machine Learning, 2025: p. 191-225.
9. Khedkar, N.R., M. Sindkhedkar, and A. Joseph, *Fragment-based drug discovery: Small fragments, big impact– Success stories of approved oncology therapeutics.* Bioorganic Chemistry, 2025: p. 108197.
10. Khandakar, S., et al., *Unveiling early detection and prevention of cancer: Machine learning and deep learning approaches.* Educational Administration: Theory and Practice, 2024. **30**(5): p. 14614-14628.
11. Bhatia, N., M.M.U. Khan, and S. Arora, *The Role of Artificial Intelligence in Revolutionizing Pharmacological Research.* Current Pharmacology Reports, 2024. **10**(6): p. 323-329.
12. Fatima, S., *Transforming Healthcare with AI and Machine Learning: Revolutionizing Patient Care Through Advanced Analytics.* International Journal of Education and Science Research Review, 2024. **11**.
13. Zhang, Y., et al., *Application of artificial intelligence in drug–drug interactions prediction: a review.* Journal of chemical information and modeling, 2023. **64**(7): p. 2158-2173.
14. Anklam, E., et al., *Emerging technologies and their impact on regulatory science.* Experimental Biology and Medicine, 2022. **247**(1): p. 1-75.
15. Yang, S. and S. Kar, *Application of artificial intelligence and machine learning in early detection of adverse drug reactions (ADRs) and drug-induced toxicity.* Artificial Intelligence Chemistry, 2023. **1**(2): p. 100011.
16. Dadlani, M., A. Wali, and K. Mukerjee, *The Art and Science of Frugal Innovation*. 2022: Penguin Random House India Private Limited.
17. Saeed, H. and I. El Naqa, *Artificial intelligence in clinical trials*, in *Machine and Deep Learning in Oncology, Medical Physics and Radiology*. 2022, Springer. p. 453-501.
18. Sahu, M., et al., *Artificial intelligence and machine learning in precision medicine: A paradigm shift in big data analysis.* Progress in molecular biology and translational science, 2022. **190**(1): p. 57-100.
19. Kulkarni, V., et al., *drug repurposing: an effective tool in modern drug discovery.* Russian journal of bioorganic chemistry, 2023. **49**(2): p. 157-166.
20. Mishra, A.S., M. Vasanthan, and S.P. Malliappan, *Drug repurposing: A leading strategy for new threats and targets.* ACS pharmacology & translational science, 2024. **7**(4): p. 915-932.
21. Choudhury, C., N.A. Murugan, and U.D. Priyakumar, *Structure-based drug repurposing: Traditional and advanced AI/ML-aided methods.* Drug discovery today, 2022. **27**(7): p. 1847-1861.
22. Boniolo, F., et al., *Artificial intelligence in early drug discovery enabling precision medicine.* Expert Opinion on Drug Discovery, 2021. **16**(9): p. 991-1007.
23. Tanoli, Z., M. Vähä-Koskela, and T. Aittokallio, *Artificial intelligence, machine learning, and drug repurposing in cancer.* Expert opinion on drug discovery, 2021. **16**(9): p. 977-989.
24. Muzio, G., L. O'Bray, and K. Borgwardt, *Biological network analysis with deep learning.* Briefings in bioinformatics, 2021. **22**(2): p. 1515-1530.
25. Cong, Y. and T. Endo, *Multi-omics and artificial intelligence-guided drug repositioning: Prospects, challenges, and lessons learned from COVID-19.* OMICS: A Journal of Integrative Biology, 2022. **26**(7): p. 361-371.
26. Patel, U.S., et al., *A newer approach to Parkinson's disease: Addressing therapeutic features, repurposing drugs and the latest concepts with future goals.* 2025.
27. Wan, Z., et al., *Applications of Artificial Intelligence in Drug Repurposing.* Advanced Science, 2025: p. 2411325.
28. Ferrara, M., et al. *Risk management and patient safety in the artificial intelligence era: a systematic review.* in *healthcare*. 2024. MDPI.
29. Haick, H. and N. Tang, *Artificial intelligence in medical sensors for clinical decisions.* ACS nano, 2021. **15**(3): p. 3557-3567.
30. Grigoriou, S., *Parkinson's disease: aspects of add-on medications in motor and non-motor symptoms.* 2024.
31. Johnson, K.B., et al., *Precision medicine, AI, and the future of personalized health care.* Clinical and translational science, 2021. **14**(1): p. 86-93.
32. Quazi, S., *Artificial intelligence and machine learning in precision and genomic medicine.* Medical Oncology, 2022. **39**(8): p. 120.
33. Ahire, Y.S., et al., *Advanced Applications of Artificial Intelligence in Pharmacovigilance: Current Trends and Future Perspectives.* J. Pharm. Res, 2024. **23**(1): p. 23-33.
34. Badria, F.A. and A.A. Elgazar, *Optimizing Pharmacovigilance in an Era of Accelerating Innovation.* 2024.
35. Khinvasara, T., N. Tzenios, and A. Shankar, *Post-market surveillance of medical devices using AI.* Journal of Complementary and Alternative Medical Research, 2024. **25**(7): p. 108-122.
36. Al-Worafi, Y.M., *Technology for drug safety: Current status and future developments*. 2023: Springer.
37. Sayal, A., et al., *Revolutionizing Drug Discovery: The Role of AI and Machine Learning in Accelerating Medicinal Advancements.* Artificial Intelligence and Machine Learning in Drug Design and Development, 2024: p. 189-221.
38. Shingari, N. and B. Mago. *The Importance of Data Encryption in Ensuring the Confidentiality and Security of Financial Records of Medical Health.* in *2024 IEEE International Conference on Interdisciplinary Approaches in Technology and Management for Social Innovation (IATMSI)*. 2024. IEEE.
39. Turkstani, H.A., et al., *Privacy and Confidentiality in Healthcare: Best Practices for Protecting Patient Information.* 2025.
40. Mirakhori, F. and S.K. Niazi, *Harnessing the AI/ML in Drug and Biological Products Discovery and Development: The Regulatory Perspective.* Pharmaceuticals, 2025. **18**(1): p. 47.
41. Ajmal, C., et al., *Innovative Approaches in Regulatory Affairs: Leveraging Artificial Intelligence and Machine Learning for Efficient Compliance and Decision-Making.* The AAPS Journal, 2025. **27**(1): p. 22.
42. Bose, M., *Bias in AI: A Societal Threat: A Look Beyond the Tech*, in *Open AI and Computational Intelligence for Society 5.0*. 2025, IGI Global Scientific Publishing. p. 197-224.
43. Esomonu, N.P.-M., *Utilizing AI and Big Data for Predictive Insights on*

Institutional Performance and Student Success: A Data-Driven Approach to Quality Assurance. AI and Ethics, Academic Integrity and the Future of Quality Assurance in Higher Education: p. 29.
44. Ressnerova, A., Z. Heger, and M. Pumera, *Translational nanorobotics breaking through biological membranes.* Chemical Society Reviews, 2025.
45. Akande, A., et al., *Power and Political Skill in the Workplace: Navigating Leadership, Followership, and Management Through Influence and Organizational Politics-Much Like the Weather?*, in *Power, Politics and Influence: Exercising Followership, Leadership, and Practicing Politics*. 2025, Springer. p. 3-34.
46. Zhang, S., et al., *The role and application of bioinformatics techniques and tools in drug discovery.* Frontiers in Pharmacology, 2025. **16**: p. 1547131.
47. Ukoba, K. and T.-C. Jen, *Challenges and Opportunities of Thin Films and 3D Printing.* Shaping Tomorrow: Thin Films and 3D Printing in the Fourth Industrial Revolution 1: Fundamentals, 2025: p. 235-325.
48. Mazumdar, H., et al., *Artificial intelligence for personalized nanomedicine; from material selection to patient outcomes.* Expert Opinion on Drug Delivery, 2025. **22**(1): p. 85-108.
49. Patel, S., D. Yadav, and D. Kumar, *Integrating machine learning to customize chemotherapy for oral cancer patients.* Oral Oncology Reports, 2025. **13**: p. 100711.
50. Garg, P., et al., *Artificial Intelligence–Driven Computational Approaches in the Development of Anticancer Drugs.* Cancers, 2024. **16**(22): p. 3884.
51. Mann, M., et al., *Artificial intelligence for proteomics and biomarker discovery.* Cell systems, 2021. **12**(8): p. 759-770.
52. Hunter, B., S. Hindocha, and R.W. Lee, *The role of artificial intelligence in early cancer diagnosis.* Cancers, 2022. **14**(6): p. 1524.
53. Mak, K.-K., Y.-H. Wong, and M.R. Pichika, *Artificial intelligence in drug discovery and development.* Drug discovery and evaluation: safety and pharmacokinetic assays, 2024: p. 1461-1498.
54. Huang, D., et al., *AI-driven drug discovery:: accelerating the development of novel therapeutics in biopharmaceuticals.* Journal of Knowledge Learning and Science Technology ISSN: 2959-6386 (online), 2024. **3**(3): p. 206-224.
55. Lattanzi, W., et al., *Basic and preclinical research for personalized medicine.* Journal of Personalized Medicine, 2021. **11**(5): p. 354.

HOW TO CITE THIS ARTICLE: Tomar P, Goel F, Pal A, Garg VK. The Future of Drug Development: Leveraging AI for Faster and Safer Innovation. *J Adv Sci Res*. 2025;16(04): 5-11 **DOI:** 10.55218/JASR.2025160402